{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:23:55Z","timestamp":1787837035740,"version":"build-2784847793"},"reference-count":54,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"unspecified","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,6,22]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This post hoc analysis of the SELECT-PsA 2 study evaluated long-term efficacy and safety of upadacitinib 15\u2009mg once daily in patients with psoriatic arthritis (PsA) and exposure to one prior tumour necrosis factor inhibitor (TNFi).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were randomised to upadacitinib 15\u2009mg once daily or placebo (switched to upadacitinib at week 24). Efficacy assessments 20%\/50%\/70% improvement in American College of Rheumatology response criteria (ACR20\/50\/70), minimal disease activity (MDA), 75%\/90% improvement in Psoriasis Area Severity Index Score (PASI75\/90), pain) were conducted through 152 weeks. Analyses evaluated the impact of prior TNFi exposure duration, skin improvement by location and early pain response as a predictor of long-term MDA. Safety was reported as treatment-emergent adverse events through week 152.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 195 patients with exposure to one prior TNFi, 90 and 105 were randomised to upadacitinib 15\u2009mg once daily and placebo, respectively. More patients randomised to upadacitinib 15\u2009mg once daily versus placebo achieved ACR20 (57.8% vs 21.9%), ACR50 (37.8% vs 9.5%), ACR70 (22.2% vs 0%) and MDA (24.4% vs 2.9%) at week 24. Responses were maintained or improved through week 152. Patients who switched from placebo at week 24 achieved sustained PASI75\/90 responses across different anatomical regions. Efficacy was generally similar regardless of the duration of prior TNFi exposure in sensitivity and tertile analyses. Lower pain scores at weeks 2 and 12 predicted MDA achievement at week 152. No new safety signals were identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Upadacitinib 15\u2009mg once daily demonstrated sustained efficacy and an acceptable safety profile in patients with PsA and exposure to one prior TNFi, irrespective of the duration of previous TNFi exposure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-006655","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:10:25Z","timestamp":1787836225000},"page":"e006655","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of upadacitinib in patients with psoriatic arthritis and exposure to one anti-TNF: post hoc analysis of SELECT-PsA 2"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-663X","authenticated-orcid":false,"given":"Laura C","family":"Coates","sequence":"first","affiliation":[{"name":"NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"},{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip","family":"Mease","sequence":"additional","affiliation":[{"name":"Rheumatology Research, Providence Swedish Medical Center, University of Washington School of Medicine, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[{"name":"Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, The University of California at San Diego, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F","family":"Merola","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center, O\u2019Donnell School of Public Health, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6520-5619","authenticated-orcid":false,"given":"Marina","family":"Magrey","sequence":"additional","affiliation":[{"name":"Case Western Reserve University, University Hospitals, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Iyile","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Zhou","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Novelli","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Lagunes","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arathi R","family":"Setty","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3561-5932","authenticated-orcid":false,"given":"Filip","family":"Van den Bosch","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Pediatrics, Ghent University, and VIB Center for Inflammation Research, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"2026082706101475000_12.3.e006655.1","first-page":"52","article-title":"GRAPPA treatment recommendations: 2021 update","volume":"49","author":"Coates","year":"2022","journal-title":"J Rheumatol"},{"key":"2026082706101475000_12.3.e006655.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159"},{"key":"2026082706101475000_12.3.e006655.3","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-016-0029-z"},{"key":"2026082706101475000_12.3.e006655.4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker365"},{"key":"2026082706101475000_12.3.e006655.5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/acr.23789","article-title":"Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026082706101475000_12.3.e006655.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225531"},{"key":"2026082706101475000_12.3.e006655.7","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2026082706101475000_12.3.e006655.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208337"},{"key":"2026082706101475000_12.3.e006655.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211734"},{"key":"2026082706101475000_12.3.e006655.10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170449"},{"key":"2026082706101475000_12.3.e006655.11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160275"},{"key":"2026082706101475000_12.3.e006655.12","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s40744-023-00574-w","article-title":"Difficult to treat and refractory to treatment in psoriatic arthritis","volume":"10","author":"Lubrano","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2026082706101475000_12.3.e006655.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203696"},{"key":"2026082706101475000_12.3.e006655.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.02.001"},{"key":"2026082706101475000_12.3.e006655.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211568"},{"key":"2026082706101475000_12.3.e006655.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204655"},{"key":"2026082706101475000_12.3.e006655.17","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1136\/annrheumdis-2024-eular.914","article-title":"AB0869 Real-world burden of uncontrolled disease despite treatment with tumor necrosis factor inhibitors among axial spondyloarthritis patients in the CorEvitas Psoriatic Arthritis\/Spondyloarthritis Registry","volume":"83","author":"Ogdie","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026082706101475000_12.3.e006655.18","doi-asserted-by":"crossref","DOI":"10.1186\/ar1941","article-title":"Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis: data from the Spanish registry BIOBADASER","volume":"8","author":"Carmona","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"2026082706101475000_12.3.e006655.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202347"},{"key":"2026082706101475000_12.3.e006655.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.37876"},{"key":"2026082706101475000_12.3.e006655.21","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3593-x"},{"key":"2026082706101475000_12.3.e006655.22","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.073544"},{"key":"2026082706101475000_12.3.e006655.23","doi-asserted-by":"crossref","DOI":"10.1186\/ar2670","article-title":"Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register","volume":"11","author":"Saad","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"2026082706101475000_12.3.e006655.24","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq326"},{"key":"2026082706101475000_12.3.e006655.25","unstructured":"RINVOQ\u00ae (upadacitinib) extended-release tablets, for oral use. 2022. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rinvoq-epar-product-information_en.pdf [Accessed 15 Dec 2025]."},{"key":"2026082706101475000_12.3.e006655.26","unstructured":"RINVOQ\u00ae (upadacitinib) extended-release tablets, for oral use. 2022. Available: https:\/\/www.rxabbvie.com\/pdf\/rinvoq_pi.pdf [Accessed 15 Dec 2025]."},{"key":"2026082706101475000_12.3.e006655.27","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa2413449","article-title":"A phase 3 trial of upadacitinib for giant-cell arteritis","volume":"392","author":"Blockmans","year":"2025","journal-title":"N Engl J Med"},{"key":"2026082706101475000_12.3.e006655.28","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.cgh.2024.02.027","article-title":"Upadacitinib reduces Crohn\u2019s disease symptoms within the first week of induction therapy","volume":"22","author":"Colombel","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026082706101475000_12.3.e006655.29","doi-asserted-by":"crossref","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol"},{"key":"2026082706101475000_12.3.e006655.30","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1002\/cpt.3441","article-title":"Extrapolation of upadacitinib efficacy in juvenile idiopathic arthritis leveraging pharmacokinetics, exposure\u2013response models, and real-world patient data","volume":"116","author":"Qian","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"2026082706101475000_12.3.e006655.31","first-page":"2286","article-title":"Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study","volume":"41","author":"Mease","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"2026082706101475000_12.3.e006655.32","article-title":"Psoriasis management challenges regarding difficult-to-treat areas: therapeutic decision and effectiveness","volume":"12","author":"Nicolescu","year":"2022","journal-title":"Life (Basel)"},{"key":"2026082706101475000_12.3.e006655.33","doi-asserted-by":"crossref","DOI":"10.1093\/rap\/rky042","article-title":"Long-term effectiveness of tumour necrosis factor-\u03b1 inhibitor treatment for psoriatic arthritis in the UK: a multicentre retrospective study","volume":"2","author":"Clunie","year":"2018","journal-title":"Rheumatol Adv Pract"},{"key":"2026082706101475000_12.3.e006655.34","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/acr.20162","article-title":"Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort","volume":"62","author":"Coates","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026082706101475000_12.3.e006655.35","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/acr.23249","article-title":"Clinical characteristics, disease activity, and patient-reported outcomes in psoriatic arthritis patients with dactylitis or enthesitis: results from the Corrona Psoriatic Arthritis\/Spondyloarthritis Registry","volume":"69","author":"Mease","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026082706101475000_12.3.e006655.36","first-page":"2870","article-title":"Predictors of early minimal disease activity in PsA patients treated with anti-TNF in a real-world registry","volume":"67","author":"Zummer","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2026082706101475000_12.3.e006655.37","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000596","article-title":"Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis: data from the British Society for Rheumatology Biologics Register","volume":"4","author":"Fagerli","year":"2018","journal-title":"RMD Open"},{"key":"2026082706101475000_12.3.e006655.38","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/acr.23567","article-title":"Incidence and prevalence of major adverse cardiovascular events in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis","volume":"70","author":"Lauper","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026082706101475000_12.3.e006655.39","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/RHU.0000000000000306","article-title":"Rates of cardiovascular disease and major adverse cardiovascular events in patients with psoriatic arthritis compared to patients without psoriatic arthritis","volume":"21","author":"Li","year":"2015","journal-title":"J Clin Rheumatol"},{"key":"2026082706101475000_12.3.e006655.40","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216102"},{"key":"2026082706101475000_12.3.e006655.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152416"},{"key":"2026082706101475000_12.3.e006655.42","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx145"},{"key":"2026082706101475000_12.3.e006655.43","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/rheumatology\/keab522","article-title":"Risk of major adverse cardiovascular events in patients initiating biologics\/apremilast for psoriatic arthritis: a nationwide cohort study","volume":"61","author":"Pina Vegas","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026082706101475000_12.3.e006655.44","doi-asserted-by":"crossref","DOI":"10.1186\/s41927-019-0094-3","article-title":"Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics","volume":"3","author":"Ritchlin","year":"2019","journal-title":"BMC Rheumatol"},{"key":"2026082706101475000_12.3.e006655.45","first-page":"63","article-title":"Burden of herpes zoster among patients with psoriatic arthritis in the United States","volume":"14","author":"Singer","year":"2024","journal-title":"Psoriasis (Auckl)"},{"key":"2026082706101475000_12.3.e006655.46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30419-2"},{"key":"2026082706101475000_12.3.e006655.47","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamadermatol.2020.0024","article-title":"Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"156","author":"Vaengebjerg","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2026082706101475000_12.3.e006655.48","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.39670","article-title":"Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2026082706101475000_12.3.e006655.49","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000581"},{"key":"2026082706101475000_12.3.e006655.50","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003064","article-title":"Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies","volume":"9","author":"Aureal","year":"2023","journal-title":"RMD Open"},{"key":"2026082706101475000_12.3.e006655.51","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31115-2"},{"key":"2026082706101475000_12.3.e006655.52","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026082706101475000_12.3.e006655.53","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001392","article-title":"Risk of venous thromboembolism in immune-mediated inflammatory diseases: a UK matched cohort study","volume":"6","author":"Galloway","year":"2020","journal-title":"RMD Open"},{"key":"2026082706101475000_12.3.e006655.54","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.38385","article-title":"A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort","volume":"66","author":"Gross","year":"2014","journal-title":"Arthritis Rheumatol"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-006655","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:10:31Z","timestamp":1787836231000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-006655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":54,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,8,27]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/rmdopen-2025-006655"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-006655","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}